Nearly 40% of type 2 diabetes patients stop taking their second-line medication, finds study medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
A new study found half of patients who use a new class of injected drugs that includes blockbusters like Ozempic (semaglutide) and Mounjaro (tirzepatide) quit them within a year.
<p>Most patients with Type 2 diabetes will end up needing to add a second-line medication after metformin — the go-to primary drug for glucose management — to control their blood sugar levels. But adherence to these second-line drugs can be hit or miss, reports a new Northwestern Medicine study. Among patients prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs), half (50%) discontinued treatment. </p>
Nearly 40% of Type 2 diabetes patients stop taking their second-line medication sciencedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencedaily.com Daily Mail and Mail on Sunday newspapers.
A new study found half of patients who use a new class of injected drugs that includes blockbusters like Ozempic (semaglutide) and Mounjaro (tirzepatide) quit them within a year.